A Relative Bioavailability Study of FOR-6219 in Capsule and Tablet Formulations

Relative Bioavailability Clinical Trial

Official title:
A Phase 1, Randomised, Open-Label, Three-way, Three-period, Crossover Relative Bioavailability Study to Assess the Single-Dose Pharmacokinetics of FOR-6219 in Capsule and Tablet Formulations in Postmenopausal Women

Status Completed

Clinical Trial Summary

This is a phase 1, randomised, open-label, three-way, three-period, crossover relative bioavailability study to assess the single-dose pharmacokinetics of FOR-6219 in capsule and tablet formulations in postmenopausal women. The effect of high-fat food on the pharmacokinetics of the tablet formulation will also be evaluated. A total of twelve, post-menopausal women, will be randomised to receive a single oral dose of FOR-6219 in three treatment periods: capsule formulation (fasted); tablet formulation (fed); tablet formulation (fasted)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Relative Bioavailability

Clinical Trial Details

NCT number	NCT04686669
Study type	Interventional
Source	Forendo Pharma Ltd
Contact
Status	Completed
Phase	Phase 1
Start date	December 10, 2020
Completion date	January 16, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02052349` - Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects	Phase 1
Completed	`NCT01911741` - A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects	Phase 1
Active, not recruiting	`NCT03154840` - Relative Bioavailability Among Different Eutropin Formulations	Phase 1
Completed	`NCT04814472` - Healthy Volunteer Study Comparing Tablet and Oral Solution Formulations	Phase 1
Completed	`NCT03934333` - A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (ELBRUS)	Phase 1
Not yet recruiting	`NCT06025344` - A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml)	Phase 1
Not yet recruiting	`NCT06025318` - An Evaluation of the Effect of Food on the PK of a Novel PanCytoVir™ Suspension (100mg/ml), in Healthy, Adult Volunteers	Phase 1
Completed	`NCT03483259` - To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers	Phase 1
Completed	`NCT05296382` - Bioavailability of Tebipenem (SPR994) Crushed Tablet	Phase 1